AtriCure Inc is a medical device company specializing in the development and manufacturing of solutions for the treatment of atrial fibrillation and other cardiac disorders. The company's business model primarily revolves around the research, development, production, and commercialization of innovative technologies and surgical devices. By offering advanced cardiac ablation systems, surgical instruments, and related tools, AtriCure Inc aims to provide healthcare professionals with effective solutions for improving patient outcomes in the field of cardiac surgery. As a leading player in the medical device industry, AtriCure Inc embraces a customer-centric approach, focusing on delivering high-quality products and comprehensive support to healthcare providers globally.

AtriCure Inc is primarily active in the healthcare and medical device industries.

The main competitors of AtriCure Inc in the market include Medtronic plc, Boston Scientific Corporation, and Johnson & Johnson.

AtriCure Inc is a leading medical device company specializing in surgical ablation systems for the treatment of atrial fibrillation and other cardiac arrhythmias. Founded in 2000, AtriCure has been dedicated to advancing innovative technologies and techniques to deliver optimal patient outcomes. With a strong focus on research and development, the company has constantly evolved to provide state-of-the-art solutions for cardiac surgeons and patients. AtriCure's commitment to excellence has earned it a reputation as a trusted leader in the industry. Today, it continues to revolutionize the field of cardiac ablation with its comprehensive portfolio of products and a relentless pursuit of technological advancements.

AtriCure Inc, a leading medical device company, has achieved several significant milestones. Notably, the company received approval from the U.S. FDA for its AtriClip® System, a revolutionary device that aids in the prevention of stroke during open-heart surgeries. Additionally, AtriCure Inc has successfully expanded its international presence by obtaining regulatory approvals in Europe, Canada, and other countries for the AtriCure® EPi-Sense® System and other innovative products. Moreover, the company has witnessed considerable growth through strategic acquisitions, such as the purchase of SentreHEART, further enhancing its portfolio of advanced cardiac surgical solutions. These milestones highlight AtriCure Inc's commitment to pioneering advancements in surgical technologies to improve patient outcomes.

AtriCure Inc is primarily present in various countries and regions across the world. The company has a global presence with a focus on North America, Europe, and Asia. AtriCure operates in the United States, where its headquarters are based, and serves customers across the country. It also has a significant presence in European markets, including countries like Germany, France, the United Kingdom, and Italy. Additionally, AtriCure has been expanding its reach in Asia, including markets such as China, Japan, and South Korea. With its widespread presence, AtriCure Inc caters to a diverse range of customers globally.

AtriCure Inc represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy, the company focuses on delivering groundbreaking solutions for the treatment of atrial fibrillation and other cardiac conditions. AtriCure Inc consistently strives to improve patient outcomes and enhance the quality of life through their innovative medical technologies. The company's commitment to research, development, and continuous improvement enables them to provide cutting-edge solutions that address the evolving needs of patients and healthcare providers. AtriCure Inc's dedication to excellence and patient care sets them apart in the medical device industry.

Analysts currently set an average price target of 53,83 USD for the AtriCure stock (median: 51,00 USD), implying +42,6 % versus the latest price. The consensus is based on 15 analyst ratings.

AtriCure Analyytikkojen kursstavoitteet 2026

15 analysts currently rate the AtriCure stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect AtriCure to generate revenue of 606,13 M USD and earnings per share of 0,11 USD.

AtriCure Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the AtriCure share trades at 34,55 EUR (39,77 USD).

The AtriCure share (ATRC) is listed on 1 stock exchanges, including: NASDAQ (ATRC).

AtriCure Inc. is a medical company specializing in the development and sale of cardiology devices. The company offers a wide range of products that can be used for the treatment of heart diseases. The company is divided into three main segments: cardiology, surgery, and pacing. In the cardiology segment, AtriCure offers devices that can be used to restore normal heart rhythms. These devices are commonly used in patients with atrial fibrillation or other cardiac arrhythmias. The surgical segment of AtriCure focuses on the development of devices that can be used in heart surgeries. This includes instruments for tissue removal and devices to support the heart-lung circulation during the operation. The third segment of AtriCure is the pacing segment. Here, the company sells devices that can be used to regulate the heartbeat. They are typically used in patients with cardiac arrhythmias. One of AtriCure's most well-known products is the bipolar cutting and coagulation device. This device is commonly used in cardiac surgeries and allows surgeons to remove tissue quickly and precisely. Another product from AtriCure is the AtriClip system. This is a clip system that is used during heart surgery to close off the left atrium. This can help reduce the risk of atrial fibrillation after the operation. Overall, AtriCure has developed a wide range of medical devices tailored to the needs of cardiology and surgical patients. The company's products are known for their high quality and reliability. The company is constantly striving to develop new, innovative products that have the potential to improve the surgical treatment of heart diseases. An important part of AtriCure's business model is collaboration with other companies and institutions. The company works closely with clinicians, scientists, and companies in the medical industry to develop and test innovative products. To drive the company's growth, AtriCure has made a number of strategic acquisitions. For example, in 2019, the company acquired SentreHeart, which has developed an innovative procedure for the treatment of atrial fibrillation. Overall, AtriCure's business model is focused on continuous improvement and innovation. The company aims to develop high-quality products that can save lives and improve the treatment of heart diseases. AtriCure is continually working to build partnerships and drive the growth of the company to improve patient care in the cardiology community.

odotettu liikevaihto AtriCure on 606,13 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto AtriCure on 5,33 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

AtriCure:n hinta-voitto-suhde (P/E) on tällä hetkellä 364,87. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan AtriCure-osakkeen arvostusta.

AtriCure:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,21. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii AtriCure-osakkeen arvostuskennuslukuna.

AtriCure:n Eulpool-laatuscore on 3/10.

AtriCure:n ISIN on US04963C2098. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

AtriCure:n WKN on A0ES9W. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

AtriCure:n ticker on ATRC. Tämä pörssinoteeraus käytetään AtriCure-osakkeiden kauppaan pörssissä.

AtriCure maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

AtriCure kuuluu sektoriin 'Terveydenhuolto'.

AtriCure:n osingot jaetaan valuutassa USD.